LivingGLP1
parallel randomized trial

EGRABINS1

The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Non-Stroke Volunteers (EGRABINS1)

Other conditionsNCT02838589S000341

Design

Randomized
30
Start year
2016
Treatment
0.14 weeks, follow-up 0.14 weeks
Countries
Denmark (1 sites)
Sponsor
Christina Kruuse (investigator initiated) (non industry)
Eligibility
healthy volunteers over 50 years without diabetes or cerebrovascular disease

Conduct and analysis

Blinding
double blind
Sequence generation
not reported
Allocation concealment
pharmacy or sealed
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
randomized
Missing data
none

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1exenatide
Exenatide 5 ug single dose
lifestyle: none1515
A2Placebo
Placebo saline single dose
lifestyle: none1515

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticExenatide 5 ug single dose
A1
Placebo
A2
Whole trial
ALL
agemean (years)61.363.3
agesd (years)6.29.1
bmimean (kg/m2)26.726.1
bmisd (kg/m2)3.84.5
femalen85
hba1cmean (mmol/mol)33.334.5
hba1csd (mmol/mol)5.03.0
other hypertensionn42
sbpmean (mmHg)133.9129.2
sbpsd (mmHg)19.410.2
weightmean (kg)79.6
weightsd (kg)12.7

Results

4 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Serious adverse events (2 lines; O25)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 15not stated; randomized; R0014007:Results
A2events0 / 15not stated; randomized; R0014007:Results
Nausea (2 lines; O27A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events3 / 15not stated; randomized; R0014007:Table 4
A2events3 / 15not stated; randomized; R0014007:Table 4